Importantly, the ratio of CSF tau/Aβ42 or CSF P-tau181/Aβ42 indicates the progression of AD pathology, which could also predict cognitive impairment in cognitively normal individuals [130,131,132]. This evidence concerns the gene MAPT and Alzheimer disease.